July 28, 2017 10:08 AM ET


Company Overview of MSD K.K.

Company Overview

MSD K.K. develops, manufactures, and sells pharmaceutical products in Japan. It offers prescription drugs and vaccines in various therapeutic areas, including cardiovascular, respiratory, hepatitis, bone and skin diseases, central nervous system, anesthesiology, cancer, women’s health, and ophthalmic diseases. MSD K.K. was formerly known as Banyu Pharmaceutical Co., Ltd. and changed its name to MSD K.K. in October, 2010. The company was founded in 1915 and is headquartered in Tokyo, Japan. MSD K.K. operates as a subsidiary of Merck & Co. Inc.

Kitanomaru Square

1-13-12, Kudan-kita


Tokyo,  102-8667


Founded in 1915


81 3 6272 1000


81 3 6238 9057

Key Executives for MSD K.K.

Managing Director
President and Representative Director
Senior Vice President, Head of Administration Division, and Executive Director
Senior Vice President and Head of Marketing & Sales Division
Deputy Head of Production Division
Compensation as of Fiscal Year 2017.

MSD K.K. Key Developments

MSD K.K. Presents at The 14th Annual BIO Asia International Conference, Mar-14-2017

MSD K.K. Presents at The 14th Annual BIO Asia International Conference, Mar-14-2017 . Venue: Grand Hyatt Tokyo, Tokyo, Japan. Speakers: Yoko Nakata.

MSD KK Presents at 13th Annual BIO Asia International Conference 2016, Mar-16-2016 10:30 AM

MSD KK Presents at 13th Annual BIO Asia International Conference 2016, Mar-16-2016 10:30 AM. Venue: Grand Hyatt, Tokyo, Japan. Speakers: Tomoko Satoh, Executive Director, Scientific Partnering, MRL Business Development & Licensing.

MSD Submits New Drug Application for Antiallergic Agent, Desloratadine to be Co-Marketed with Kyorin

MSD K.K. submitted a new drug application for an antiallergic agent, desloratadine (generic name). In November 2014, MSD, through its affiliate, signed a co-marketing agreement in Japan for desloratadine with Kyorin Pharmaceutical Co. Ltd. With the agreement, MSD and Kyorin will be co-marketing desloratadine after its approval and launch. Desloratadine is a novel and second generation histamine H1-receptor antagonist. While it is under NDA review in Japan for the indications of allergic rhinitis, hives, and itching resulting from skin diseases (eczema/dermatitis, pruritus cutaneous), desloratadine has already had approved in more than 120 countries including the United States and Europe. MSD is committed to the improvement of QOL of Japanese people by developing and delivering innovative medicines. This NDA submission reflects the company's commitment demonstrated in the respiratory and allergic disease areas.

Similar Private Companies By Industry

Company Name Region
ABsize Inc. Asia
AccuRna, Inc. Asia
ACE Japan, L.L.C. Asia
AETAS Pharma Co.,Ltd. Asia
AIP Corporation Asia

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact MSD K.K., please visit www.msd.co.jp. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.